Aptorum Group Limited (APM)
| Market Cap | 10.21M |
| Revenue (ttm) | 1.20M |
| Net Income (ttm) | -13.40M |
| Shares Out | 4.17M |
| EPS (ttm) | -3.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,428 |
| Open | 2.42 |
| Previous Close | 2.48 |
| Day's Range | 2.31 - 2.48 |
| 52-Week Range | 1.36 - 9.00 |
| Beta | -0.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 9, 2024 |
About APM
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c... [Read more]
Financial Performance
In 2022, Aptorum Group's revenue was $1.30 million, a decrease of -15.95% compared to the previous year's $1.54 million. Losses were -$9.80 million, -60.88% less than in 2021.
Financial StatementsNews
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Na...
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the t...
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (the “Company”) (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading...
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary A...
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to...
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding...
Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Mon...
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the devel...
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Announces 1-for-10 Reverse Stock Split
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / November 25, 2022 / RedChip Companies will air a new interview Aptorum Group Limited (NASDAQ:APM)(Euronext Paris:APM), a clinical stage biopharmaceutical company dedicated t...
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News:
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...